Adds details from the letter, context in paragraphs 3-5

By Maggie Fick, Bhanvi Satija and Patricia Weiss

LONDON/FRANKFURT, June 10 (Reuters) - Pfizer PFE.N is reviewing the timing and scope of planned investments in Germany, CEO Albert Bourla said in a letter to Chancellor Friedrich Merz, citing the government's policy proposals that would lower drug prices.

The letter, dated June 9 and seen by Reuters on Wednesday, was first reported by German business newspaper Handelsblatt.

Bourla wrote that the proposals call into question the predictability required for the pharmaceutical industry's long-term investment decisions.

"As a result, we are reviewing our external engagements as well as the timing, scope, and future prioritization of certain planned investments in Germany," the letter read.

It comes the week after ⁠U.S.-based Eli Lilly LLY.N said it would halve its $2.3 billion ​investment in Germany and German drugmaker Boehringer Ingelheim scrapped ​its €900 million plans, both citing the government's planned healthcare cost-cutting measures.